enGene Holdings Inc
ENGN
Company Profile
Business description
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Contact
4868 Rue Levy
Suite 220
Saint-LaurentQCH4R 2P1
CANT: +1 514 332-4888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
57
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.70 | 41.30 | 0.46% |
| CAC 40 | 8,123.88 | 27.50 | -0.34% |
| DAX 40 | 24,308.44 | 20.04 | 0.08% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,858.13 | 39.29 | -0.40% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 50,402.39 | 895.18 | 1.81% |
| NZX 50 Index | 13,508.30 | 174.90 | 1.31% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,699.90 | 39.70 | 0.46% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |